murinus</i> significantly alleviated fructose-induced MASLD symptoms, characterized by reduced liver ballooning, inflammation, hepatic cholesterol, triglycerides, as well as decreased blood cholesterol, triglycerides, ALT and AST levels. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.